



Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset

Daniele Altomare^{1,20} · Clarissa Ferrari² · Anna Caroli³ · Samantha Galluzzi⁴ · Annapaola Prestia⁴ · Wiesje M. van der Flier^{5,6} · Rik Ossenkoppele^{5,7,8} · Bart Van Berckel^{5,7} · Frederik Barkhof^{7,9,10} · Charlotte E. Teunissen¹¹ · Anders Wall¹² · Stephen F. Carter^{13,14} · Michael Schöll^{8,21,22} · IL Han Choo^{13,15} · Timo Grimmer¹⁶ · Alberto Redolfi⁴ · Agneta Nordberg^{17,18} · Philip Scheltens⁵ · Alexander Drzezga¹⁹ · Giovanni B. Frisoni^{1,4,20} for the Alzheimer's Disease Neuroimaging Initiative

Received: 23 January 2019 / Revised: 16 May 2019 / Accepted: 21 June 2019 / Published online: 2 July 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract

Objective The aim of this study is to assess the impact of age at onset on the prognostic value of Alzheimer's biomarkers in a large sample of patients with mild cognitive impairment (MCI).

Methods We measured A β 42, *t*-tau, hippocampal volume on magnetic resonance imaging (MRI) and cortical metabolism on fluorodeoxyglucose–positron emission tomography (FDG-PET) in 188 MCI patients followed for at least 1 year. We categorised patients into earlier and later onset (EO/LO). Receiver operating characteristic curves and corresponding areas under the curve (AUCs) were performed to assess and compare the biomarker prognostic performances in EO and LO groups. Linear Model was adopted for estimating the time-to-progression in relation with earlier/later onset MCI groups and biomarkers.

Results In earlier onset patients, all the assessed biomarkers were able to predict cognitive decline ($p < 0.05$), with FDG-PET showing the best performance. In later onset patients, all biomarkers but *t*-tau predicted cognitive decline ($p < 0.05$). Moreover, FDG-PET alone in earlier onset patients showed a higher prognostic value than the one resulting from the combination of all the biomarkers in later onset patients (earlier onset AUC 0.935 vs later onset AUC 0.753, $p < 0.001$). Finally, FDG-PET showed a different prognostic value between earlier and later onset patients ($p = 0.040$) in time-to-progression allowing an estimate of the time free from disease.

Discussion FDG-PET may represent the most universal tool for the establishment of a prognosis in MCI patients and may be used for obtaining an onset-related estimate of the time free from disease.

Keywords Alzheimer · Cognition · Imaging · Biomarkers · FDG-PET

Introduction

Diagnostic criteria for Alzheimer's disease [1, 2] postulate that the assessment of diagnostic/pathophysiological (amyloid and tau pathology) and progression/topographical

(cortical atrophy and hypometabolism) biomarkers enhances the diagnostic accuracy. Although a large amount of data supported the accuracy of these biomarkers for the diagnosis of Alzheimer's disease at both the dementia [3–5] and the mild cognitive impairment (MCI) stages [4, 6, 7], only relative few studies compared biomarkers in terms of diagnostic and prognostic performances. FDG-PET alone showed a prognostic performance comparable to CSF A β 42 paired with hippocampal atrophy [8], while the joint use of MRI, FDG-PET, and CSF biomarkers provided the most accurate prediction of dementia [9–11]. Covariates associated with the disease, such as age at symptom onset, may affect biomarker status or level, and thus its diagnostic or prognostic performance. Indeed, younger age at onset was associated with milder hippocampal atrophy [12, 13], and

Daniele Altomare and Clarissa Ferrari contributed equally to this work.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00415-019-09441-7>) contains supplementary material, which is available to authorized users.

✉ Clarissa Ferrari
cferrari@fatebenefratelli.eu

Extended author information available on the last page of the article

greater amyloid burden [14] and parietal hypometabolism [15]. Thus, MRI exhibited higher diagnostic value for later onset [16] while FDG-PET [17] and Alzheimer's CSF biomarkers [18] showed best performance in earlier onset patients with Alzheimer's disease. However, most of these works, as well as recent papers, in which the age of onset and biomarkers level have been concurrently assessed in MCI, include relative small samples of patients and often with different cognitive profile [19–22], thus a validation on a large, homogeneous sample of amnesic MCI is desirable. A noteworthy aspect regards the quantification of biomarker ability to predict the time-to-progression. Very few studies compare biomarkers in terms of quantification of time-to-conversion [23] and, to the best of our knowledge, none faced with quantification of the effect of age at onset on the biomarker ability to estimate time-to-progression. The aim of this study was to investigate the impact of age at symptom onset on the prognostic value of Alzheimer's core biomarkers with respect to cognitive decline in a large sample of MCI patients homogeneous in terms of cognitive profile and impairment severity. Moreover, based on age of onset and biomarkers level, prediction models for the estimate of the time-to-progression was developed.

Materials and methods

Subjects

We selected patients from two independent datasets: the Alzheimer's Disease Neuroimaging Initiative (ADNI, <http://adni.loni.usc.edu>) and a harmonised European dataset (EU) of patients coming to diagnostic work-up at four independent European memory clinics (TOMC, Brescia, Italy; VUmc, Amsterdam, The Netherlands; KUHH, Stockholm, Sweden; and TUM, Munich, Germany). For a complete description of the two datasets please see online supplementary materials.

At baseline, all patients enrolled in this study (89 from ADNI, 31 from TOMC, 25 from VUmc, 17 from KUHH and 26 from TUM) were diagnosed as MCI as described by Petersen and colleagues [24], and had data on MRI, FDG-PET and CSF sampling. Biomarker status was either not available or not taken into account for the baseline diagnosis. The cognitive profile was consistent with single or multiple domain amnesic MCI. No focal ischemic lesions nor extensive microvascular disease that could be responsible for the cognitive symptoms were present on routine MR. MCI patients were followed up to detect cognitive decline, defined as (1) having dementia at follow-up, (2) getting a score less than 24 at last MMSE (this cut-off showed 66% sensitivity and 99% specificity in detecting dementia; [25], and (3) losing more than three points between first and last MMSE administration [26]. In the case a diagnosis of

incident dementia was made, only those patients diagnosed as Alzheimer's disease according to NINCDS-ADRDA criteria [27] were included in the study, while MCI patients who converted to non-Alzheimer's dementia were excluded.

Standard protocol approvals, registrations, and patient consents

Ethics/radiation committee approval of any protocol involved in the study was obtained at each centre. Written informed consent to share data for scientific research purposes was collected from each participant.

Biological markers of amyloidosis and neurodegeneration

We selected CSF A β 42 concentration as a biological marker for the absence or presence of cortical amyloid deposition. We assessed neurodegeneration using: (1) CSF total tau (*t*-tau) concentration, (2) an FDG-PET index of Alzheimer-related hypometabolism, the 'AD *t*-sum' score, calculated using the PMOD Alzheimer's Analysis for FDG PET (PALZ) tool ([28]; <http://www.pmod.com>), and (3) an MRI-based automated segmentation of age-adjusted hippocampal atrophy (*W* scores). Information on procedures, normalization and definition of normality/abnormality thresholds for the biomarkers are reported in online supplementary materials.

Statistical analysis

We pooled MCI patients from ADNI and EU datasets, and then categorized them into earlier onset (EO ≤ 70 years) and later onset (LO > 70 years) based on their age at diagnosis, under the assumption that the arrive to a memory clinic for cognitive impairment corresponds to the symptom onset. Seventy years cut-off was chosen based on: (1) recent revisions of the definition of elderly in Western countries [29–31] and (2) age distribution of our sample (mean = 71, median = 73). This cut-off allowed to obtain two almost size-balanced groups (40% in EO and 60% in LO). Moreover, to validate our results, we repeated all analyses (see online supplementary materials) re-categorising patients into EO and LO using the conventional 65 years cut-off [32]. One outlier (in EO) was identified by Tukey's inter-quantile range and excluded from the analyses.

We assessed differences between EO and LO in sociodemographic and clinical features, genotype and biomarker status and level by Mann–Whitney test (for continuous variables) or Pearson's Chi-squared test (for dichotomous variables). To assess the association of biomarker abnormality with cognitive decline, for each biomarker we divided the whole MCI group, as well as EO and LO groups, into

subgroups based on biomarker abnormality thresholds [33]. We performed survival curves and univariate Cox regression models (both crude and adjusted by age, gender, APOE, MMSE scores, and study center) individually for each of the four biomarkers in the EO, LO and whole MCI groups. Significance of differences in survival curves between normal and abnormal groups were assessed by log rank test. Hazard ratios and corresponding 95% confidence intervals (95% CI) were reported for each biomarker evaluated through Cox models.

Receiver operating characteristic (ROC) curves and corresponding areas under the curve (AUCs) were performed to assess and compare the biomarker prognostic performances in EO, LO and whole MCI groups. Within biomarker, EO and LO AUCs were compared using De Long test for two uncorrelated ROC curves [34]. Within patient group, different biomarkers AUCs were compared two by two using the Bootstrap test for two correlated ROC curves. Moreover, to take into account differences of follow-up time across patients, time-dependent ROC curves were performed.

A composite evaluation of all biomarkers significantly related to the cognitive decline was carried out by multiple Cox regression models in EO and LO patients (two separate models). Biomarkers were included in the models as continuous variables, and FDG-PET AD *t*-sum scores were polarized so that more negative values denote greater abnormality. A compound evaluation of biomarkers prognostic capability in detecting cognitive decline (for EO and LO) was obtained by the *risk scores* computed as the predicted values [35] of the Cox regression model, in which only significant biomarkers were included (EO: FDG-PET only; LO: FDG-PET, hippocampal volume, and CSF A β). We finally assessed and compared the prognostic performance, evaluated by predicted risk scores, of EO and LO through ROC curves, computing areas under the curve (AUCs). De Long test was used to compare the two (for EO and LO) uncorrelated ROC curves.

Finally, we adopted a linear model for analysing the time-to-progression in EO and LO MCI patients, where the time-to-progression (in months) was the dependent variable, whereas group (EO/LO, reference category: EO) and, respectively, CSF A β 42, CSF *t*-tau, FDG-PET, hippocampal volume were independent variables of the three Linear models. Parameters were computed both in the unadjusted model and adjusting by covariates found significant in the Cox models. In case the interaction between biomarker and group was not significant, the interaction was removed from the model. All the above analyses were performed separately also in EU and ADNI cohorts.

We performed statistical analyses using the R software (<http://www.r-project.org/>), version 3.0.2, with pROC and timeROC R package for ROC analysis; car package for generalized linear models.

Results

Below we reported results based on the age-based cut-off of 70 years. However, categorizing patients into EO and LO based on the 65 years cut-off provided very similar results (see Figures from e2 to e4 in the online supplementary materials).

Patients' descriptive features

We included 188 MCI patients with a mean follow-up of 28 (SD 14) months, of whom 76 were EO and 112 were LO. The ratio EO/LO is lower in ADNI than in EU datasets (22.5% vs 56.6%, $p < 0.001$), indicating that European centres involved a younger population than the ADNI one. EO patients had higher MMSE scores both at baseline ($p = 0.011$) and at the last follow-up ($p = 0.009$) than LO patients, showing, however, a similar MMSE yearly change ($p = 0.217$). Moreover, EO showed higher levels of CSF A β 42 ($p = 0.013$), while all the other biomarkers were similar between EO and LO patients ($p > 0.05$) (Table 1). Similarly, we did not find any difference in the proportions of biomarker normality/abnormality at baseline between EO and LO patients (Table 1). More details about socio-demographic and clinical features by study centre are reported in Table e1 of the online supplementary materials.

Effect of age at onset on the biomarker ability to predict cognitive decline

Patients with abnormal biomarkers showed significantly different survival analysis distributions than patients with normal biomarkers. In EO patients, all the assessed biomarkers showed a significant ability to predict cognitive decline, namely patients with abnormal biomarkers at baseline developed cognitive decline more rapidly than those with normal biomarkers, with FDG-PET showing the best performance (FDG-PET: unadjusted HR = 17.71, $p < 0.001$; CSF A β 42: 3.09, $p = 0.010$; CSF *t*-tau: 2.57, $p = 0.010$; hippocampal volume: 2.40, $p = 0.015$; Fig. 1a). In LO patients, all biomarkers but CSF *t*-tau were able to predict cognitive decline (FDG-PET: 3.19, $p < 0.001$; CSF A β 42: 2.41, $p = 0.011$; hippocampal volume: 2.03, $p = 0.009$; Fig. 1b). For both EO and LO groups and all biomarkers but CSF A β 42, HRs remained almost unchanged while adjusting for age, gender, APOE, baseline MMSE and study center. Similar results were obtained pooling together EO and LO MCI patients (whole MCI group: $p = 0.001$ for FDG-PET; and $p < 0.05$ for CSF *t*-tau, CSF A β 42 and hippocampal volume).

When comparing prognostic performance to detect cognitive decline of each biomarker between EO and LO

Table 1 Clinical and genetic features of 188 MCI patients categorized by age at onset (EO or LO)

	EO (≤ 70 years) N=76	LO (> 70 years) N=112	EO vs LO p value
Clinical and genetic features			
Age at symptom onset (years)	64.6 (5.8)	78.4 (4.3)	<0.001
Gender (females %)	41 (53.9%)	42 (37.5%)	0.038
Education (years) ^a	16.8 (2.9)	15.9 (2.8)	0.142
Follow-up time (months)	29.9 (17.6)	26.6 (11.4)	0.536
Baseline MMSE	27.3 (1.7)	26.7 (1.76)	0.011
Last follow-up MMSE ^b	25.7 (4.0)	24.3 (4.0)	0.009
MMSE yearly change ^b	-1.7 (4.6)	-2.0 (4.0)	0.217
ApoE $\epsilon 4$ carriers ^c	46 (62.2%)	53 (49.1%)	0.112
Biomarkers			
CSF A β 42 (z)	0.01 (1.07)	-0.31 (1.07)	0.013
% normal/% abnormal	41/59	28/72	0.086
CSF total tau (z)	-0.40 (1.32)	-0.36 (1.34)	0.755
% normal/% abnormal	55/45	53/47	0.842
FDG-PET (AD <i>t</i> -sum)	21,433.9 (23,452.8)	16,455.0 (16,774.4)	0.754
% normal/% abnormal	55/45	64/36	0.276
Hippocampal volume (w)	-2.0 (2.4)	-2.1 (2.3)	0.989
% normal/% abnormal	59/41	61/39	0.956

Values are mean (standard deviations) or frequency (percentage). MMSE yearly change was computed with the formula (MMSE at the follow-up - MMSE at the baseline)/(follow-up time/12). Normal/abnormal classification as defined in Section suppl 1.2

p denotes *p* values of Mann-Whitney test (for continuous variables) or Chi-squared test (for categorical variables)

^aMissing data: 45 for EO, 23 for LO

^bMissing data for 4 EO and 11 LO

^cMissing data for 2 for EO, 4 for LO

patients, FDG-PET showed a better ability to predict cognitive decline in EO than in LO patients (EO AUC = 0.935 vs LO AUC = 0.681, $p < 0.001$), while the other biomarkers showed similar performances in both groups ($p > 0.05$) (Fig. 2). When time-dependent ROC curves are applied, FDG-PET confirmed its high prognostic performance starting from time $t = 32$ (Figure e1 in the online supplementary materials).

When combining all the biomarkers in a multiple model, in EO patients FDG-PET was the only factor significantly associated with cognitive decline ($p < 0.001$), while in LO all biomarkers but CSF *t*-tau were associated with cognitive decline (FDG-PET and hippocampal volume: $p < 0.001$; CSF A β 42: $p = 0.021$). Moreover, the prognostic performance to detect cognitive decline of FDG-PET alone in EO patients was significantly higher than the one resulting from the combination of FDG-PET, hippocampal volume and CSF A β 42 in LO patients (multiple models: EO AUC 0.935, LO AUC 0.753; $p < 0.001$) (Fig. 3).

Effect of age at onset on the biomarker ability to predict time-to-progression

FDG-PET and hippocampal volume were the only significant predictors of time-to-progression with $p = 0.043$ and 0.032, respectively (Table 2). Moreover, the prognostic effect was statistically different between EO and LO only for FDG-PET (interaction term $p = 0.040$), whereas this interaction showed only a trend to significance ($p = 0.073$) for hippocampal volume. In particular, the negative beta coefficient of the factor Group means that in EO the time-to-progression was lower than in LO; moreover, an increase of ten thousand of AD *t*-sum (index of Alzheimer-related hypometabolism) predicts 1.69 months earlier conversion in EO MCI, and 0.81 months later conversion in LO MCI (slope LO MCI = 2.50 - 1.69 = 0.81): in others words, an enhancement of FDG-PET predicts a shorter time-to-progression in EO than in LO. Interestingly, when the linear models were adjusted for MMSE, gender and APOE, the




Fig. 1 Survival curves displaying the association of biomarker abnormality with cognitive decline by age at onset in MCI patients (a EO, b LO). Patients with normal and abnormal biomarkers are denoted by dashed and solid lines, respectively. + indicates censored cases. HR unadjusted hazard ratio (95% confidence interval) in Cox regres-

sion models. Adjusted HRs statistically differ from unadjusted HRs only for Aβ42 (in EO: adjHR=2.43 (0.81–7.25), $p=0.111$; in LO adjHR=1.94 (0.98–4.26), $p=0.064$). The most prognostic individual biomarker is FDG-PET with higher prognostic value in EO (HR 17.71) than in LO patients (HR 3.19)




Fig. 2 Receiver operating characteristic curves showing prognostic performance (discrimination of cognitive decline) of biomarkers. Values denote areas under the curve (95% confidence interval). The analysis confirms the findings of Fig. 1

prognostic effect on time-to-progression of FDG-PET and hippocampal volume were fully and partially mediated by APOE ($p=0.065$ and $p=0.037$, respectively). The

advantage of these predictive models is that they allow to estimate, given socio-demographic and clinical features, the patient-specific time-to-progression.




Fig. 3 Receiver operating characteristic curves showing the prognostic performance for cognitive decline of risk scores computed by multiple Cox regression models including biomarkers with significant effect (earlier onset: FDG-PET only; later onset: Aβ42, FDG-PET, and hippocampal volume). Biomarkers were included in the model as continuous variables. Values denote areas under the curve (95% confidence interval). The two curves were significantly different ($p < 0.001$)

Discussion

In this study, we investigated the impact of age at symptom onset on the prognostic value of Alzheimer’s biomarkers with respect to cognitive decline and its time-to-progression in a large sample of MCI patients homogeneous in terms of cognitive profile and impairment severity and all assessed by the four available biomarkers. These are two separate questions, considering that a biomarker predicting cognitive declines does not necessarily predict when cognition declines. We found that Alzheimer’s biomarkers as taken alone are able to predict the developing of cognitive decline both in EO and LO groups (except for CSF t -tau in LO), with patients with abnormal biomarkers at baseline showing an increased incidence of cognitive decline over time than those with normal biomarkers. In addition, when combining all these biomarkers, FDG-PET is the only significant predictor of cognitive decline in EO patients, and its prognostic value in this group was greater than that one obtained combining all significant biomarkers in LO patients. Moreover, with regard to time to progression, we found that FDG-PET and hippocampal volume were associated with time-to-progression, but only FDG-PET showed a different prognostic value between EO and LO patients. These results are confirmed

Table 2 Prediction of time to conversion in 76 early onset (EO) and 112 late onset (LO) MCI patients with cognitive decline in 2 years on average

	Unadjusted models Coefficients		Adjusted models Coefficients	
	(95% CI)	<i>p</i> value	(95% CI)	<i>p</i> value*
CSF Aβ 42				
<i>z</i> score	−0.67 (−3.77; 2.43)	0.672	−1.75 (−4.96; 1.50)	0.286
Group	−1.18 (−6.48; 4.11)	0.663	−0.68 (−6.04; 4.69)	0.805
CSF total tau				
<i>z</i> score	−1.09 (−2.72; 0.54)	0.193	−1.65 (−3.35; 0.04)	0.060
Group	−1.86 (−7.13; 3.41)	0.491	−1.99 (−7.27; 3.30)	0.463
FDG-PET				
<i>t</i> sum/10,000	−1.69 (−3.29; −0.09)	0.043	−1.58 (−3.23; 0.07)	0.065
Group	−8.18 (−17.48; 1.12)	0.090	−5.85 (−15.53; 3.83)	0.240
<i>t</i> sum/10,000 × group	2.50 (0.17; 4.83)	0.040	1.90 (−0.52; 4.33)	0.128
Hippocampal volume				
<i>w</i> score	1.66 (0.18; 3.14)	0.032	1.68 (0.13; 3.24)	0.037
Group	−6.74 (−14.54; 1.07)	0.094	−5.78 (−13.84; 2.29)	0.164
<i>w</i> score × group	−2.09 (−4.34; 0.16)	0.073	−1.73 (−4.07; 0.62)	0.154

Parameters were computed in linear regression models with time to conversion (in months) as dependent variable and biomarkers and group (EO vs LO) as independent variables. In the adjusted regression model, MMSE score, gender and APOE as added as further independent variables. When the interaction between biomarker and group was not significant, ($p > 0.1$) the interaction term was removed from the model; similarly when in the adjusted models the independent variables are not significant. Ten thousand *t*-sum increase was associated with 1.69 months earlier conversion in EO MCI, and 0.81 months later conversion in LO MCI (slope LO MCI = $2.50 - 1.69 = 0.81$)

1 outlier in EO, identified by Tukey’s inter-quantile range of model residuals, was excluded from each biomarker model computation

*In all adjusted models, APOE was the only significant factor with a *p* value ranged from 0.011 and 0.037 in the 4 models

also in separated analyses for EU and ADNI cohorts where the ratio EO/LO is significantly different between them.

Our findings are in line with a paper showing that FDG-PET added greater prognostic information to routine clinical tests than CSF or MRI [10]. Previous studies compared biomarker diagnostic value in EO and LO patients with Alzheimer's disease, finding highest diagnostic value for MRI in LO [16], and for FDG-PET in EO patients with Alzheimer's disease [17]. There is only one previous study examining the effect of age on the prediction of cognitive decline by MRI, CSF, and FDG-PET biomarkers in MCI patients [36]. Major findings were that in younger patients, CSF and MRI biomarkers correctly predicted about two-thirds of the conversions, while FDG-PET was only a marginally significant predictor; in the older patients MRI predicted cognitive decline, but CSF biomarkers and FDG-PET did not.

As to time-to-progression, a previous study performed in MCI subjects with evidence of amyloid pathology found that CSF *t*-tau and hippocampal atrophy can predict time-to-progression [37]. To the best of our knowledge, this is the first study assessing the impact of age at onset on predicting time-to-progression by core biomarkers. Our results suggest that both hippocampal atrophy and FDG-PET can be used (alone and together with APOE information), to provide a magnitude of time-to-progression. Although APOE emerges as key role in the disease progression, the contribution of FDG-PET and hippocampal atrophy in predicting the time-to-conversion was still (at most) significant after APOE adjustment. This groundbreaking approach allows to estimate, based on patients features, age of onset and biomarker measured values, the remaining time free from disease, and thus to allow neurologist/geriatrician to plan a specific and patient-oriented disease management. There are a number of findings deserving discussion. First, we found FDG-PET to be the best predictor of cognitive decline in particular in EO. This is likely due to EO greater hypometabolism, suggesting that the disease could be more aggressive in EO than in LO patients, or even that EO and LO patients may have different underlying pathological processes, with the former group being more homogeneous with regard to the underlying AD pathology. Indeed, the higher prognostic value of FDG-PET in EO than in LO patients suggests that cortical hypometabolism measured with AD *t*-sum, a FDG-PET index of AD-related hypometabolism, has a higher accuracy in detecting the cognitive decline due to AD as compared to A β 42, tau and hippocampal atrophy, which are common features also in neurodegenerative diseases other than AD [1]. Moreover, in EO, FDG-PET was the only factor significantly contributing to cognitive decline in the multiple model; while in LO all biomarkers but CSF *t*-tau significantly contributed. This may suggest that FDG-PET, hippocampal volume and CSF A β 42 are closely related in EO, while in LO they all independently contribute. Last, amyloid marker did show

prognostic value in both EO and LO. Despite amyloid being one of the first markers to become abnormal, amyloid negativity is associated with better outcome and amyloid positivity could be a risk factor at any age.

Current findings could have been influenced by the choice of biomarkers. Among established biomarkers of amyloid- β accumulation, we included CSF A β 42 protein concentration while amyloid imaging biomarkers, despite being widely validated, were not included due to paucity of data available. However, amyloid PET and CSF A β 42 are highly intercorrelated [38, 39], then we assume they would have led to similar results. Among biomarkers of neural degeneration or injury, we included CSF *t*-tau, FDG-PET and structural MRI biomarkers, while we decided not to include CSF phosphorylated tau due to the paucity of data available. As a biomarker denoting decreased FDG uptake on PET we chose a summary metric of Alzheimer-like hypometabolism [28], which was previously shown to provide good discrimination power between patients with Alzheimer's disease and controls [40, 41], and to be a valid marker to monitor the progression of MCI to dementia due to Alzheimer's disease [42]. Among structural MRI biomarkers, new diagnostic criteria suggest to consider atrophy in a specific topographic pattern involving medial, basal and lateral temporal lobe, and medial and lateral parietal cortices [2]. We included hippocampal volume, demonstrated to be a sensitive [43], and pathologically validated [44, 45] marker of neurodegeneration that parallels and precedes cognitive decline [46], and we computed it with an automated segmentation software (Freesurfer) to avoid bias due to different hippocampal segmentation protocols among centres.

This study has some strengths and limitations. The group of 188 MCI patients under study has all the four biomarkers available at baseline, paired with information on cognitive trajectories derived from long-term follow-up (28 months on average). Despite CSF biomarkers were a posteriori normalised among centres, the fact of having biomarkers measured in different laboratories, probably using different strategies to derive cut-offs, could have affected the study results. Moreover, similar procedures for hippocampal atrophy assessment are not yet available, and thresholds for abnormality currently vary from laboratory to laboratory, increasing error variance of the assignment to normality/abnormality. Moreover, the inclusion of data coming from different datasets (ADNI and EU) may be a source of heterogeneity. For this reason, we adjusted our Cox regression model by study centre and rerun the analyses on these two cohorts separately to further confirm our results. Cohorts analyses confirmed FDG-PET as the best biomarker in predicting the cognitive decline difference between normal and abnormal values for EO in both EU and ADNI cohorts. In LO patients, although the HR were comparable to the ones of whole sample, in some cases the results were quite far from significance

and it was basically due to the sample size of the two separated cohorts EU and ADNI. Similar consideration holds for the time to progression analysis: beta coefficients are comparable (in sign and in value) to the ones of the whole sample even if their significance was affected by the sample size. These findings support the reliability of our results. Current findings could have been influenced by the choice of the age cut-off for the definition of elderly. Although the conventional threshold is 65 years, it is worth noting that the evidence on which this definition is based on is becoming even more feeble, especially in Western countries in which the ‘rejuvenation’ and slow-age phenomena have been seen [29–31]. The age distribution of our MCI sample is coherent with these phenomena. Moreover, a recent paper showing that the cut-off of 70 years differentiates between EO and LO groups in terms of neuropsychological, not biomarker profile, better than the cut-off of 65 years conventionally used [47]. In this sense, thus, our cut-off choice constitutes both a novelty and an incentive in considering new evidence-based definition of cut-off for discriminating between young and old population. To dispel all doubts regarding the effect of age cut-off on our study results, we repeated all analyses re-categorising patients based on the cut-off of 65 years, finding very similar results (see online supplementary materials). Moreover, we used age at diagnosis as proxy of age at onset, under the assumption that the moment of arrive to a memory clinic for cognitive impairment corresponds to the symptom onset. However, these moments do not always correspond. An undeniable limit of this work regards the definition of the study population based on a syndromic rather than a clinical diagnosis. Cognitive decline was defined based on multiple outcomes. The ideal outcome would have been the onset of dementia due to Alzheimer’s disease at follow-up over an adequately long period; failing that, we included two additional outcomes (losing more than 3 points between first and last MMSE administration over a minimum time period or getting a score less than 24 at last MMSE administration), highly associated with having or being about to develop dementia. However, we cannot completely exclude that decline on the MMSE may also result from non-Alzheimer’s dementia in the future after follow-up.

Conclusion

In conclusion, this study showed that all biomarkers are able to predict cognitive decline in both age groups (except for CSF t -tau in LO), but the prognostic value of FDG-PET in EO is greater than even all combined biomarkers in LO patients. FDG-PET is also able to predict different patterns of time-to-progression between EO and LO patients, by providing, through predictive linear models, an estimate of time free from disease based on patient-specific biomarker

levels and age of onset. These results indicate that FDG-PET may represent the most universal tool for the establishment of a prognosis in MCI patients. The current findings may contribute to the development of guidelines for the use of biomarkers in clinical settings.

Acknowledgements Data used in this article were partially collected by Translational Outpatient Memory Clinic—TOMC—working group at IRCCS Centro San Giovanni di Dio Fatebenefratelli in Brescia, Italy. Contributors to the TOMC, involved in data collection, are: G Amicucci, S Archetti, L Benussi, G Binetti, L Bocchio-Chiavetto, C Bonvicini, E Canu, F Caobelli, E Cavedo, E Chittò, M Cotelli, M Gennarelli, S Galluzzi, C Geroldi, R Ghidoni, R Giubbini, UP Guerra, G Kuffenschin, G Lussignoli, D Moretti, B Paghera, M Parapini, C Porteri, M Romano, S Rosini, I Villa, R Zanardini, O Zanetti. FB is supported by the NIHR UCLH biomedical research centre. Part of the data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu>). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Funding *EU data collection and sharing*: The work was supported by the Swedish Research Council (project 05817), the Strategic Research Program in Neuroscience at Karolinska Institutet, the Swedish Brain Power. This work was also supported by the grants: sottoprogetto finalizzato Strategico 2006: “Strumenti e procedure diagnostiche per le demenze utilizzabili nella clinica ai fini della diagnosi precoce e differenziale, della individuazione delle forme a rapida o lenta progressione e delle forme con risposta ottimale alle attuali terapie”; Programma Strategico 2006, Convenzione 71; Programma Strategico 2007, Convenzione PS39, Ricerca Corrente Italian Ministry of Health. Some of the costs related to patient assessment and imaging and biomarker detection were funded thanks to an ad hoc grant from the Fitness e Solidarietà 2006 and 2007 campaigns. The analyses of MRI data presented in the paper have been performed thanks to the neuGRID platform, which has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 283562. *Alzheimer’s Disease Neuroimaging Initiative (ADNI) data*: Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (<http://www.fnih.org>). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San

Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Compliance with ethical standards

Conflicts of interest The authors have no conflicts of interest to report.

Ethical standards This study was approved by the ethics committee of each participating center and all participants were enrolled after written informed consent was obtained.

References

- Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *Lancet Neurol* 13:614–629. [https://doi.org/10.1016/S1474-4422\(14\)70090-0](https://doi.org/10.1016/S1474-4422(14)70090-0)
- Jack CRJ, Albert MS, Knopman DS et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 7:257–262. <https://doi.org/10.1016/j.jalz.2011.03.004>
- Duits FH, Martinez-Lage P, Paquet C et al (2016) Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. *Alzheimers Dement* 12:154–163. <https://doi.org/10.1016/j.jalz.2015.08.003>
- Frisoni GB, Bocchetta M, Chetelat G et al (2013) Imaging markers for Alzheimer disease: which vs how. *Neurology* 81:487–500. <https://doi.org/10.1212/WNL.0b013e31829d86e8>
- Molinuevo JL, Blennow K, Dubois B et al (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimers Dement* 10:808–817. <https://doi.org/10.1016/j.jalz.2014.03.003>
- Hansson O, Zetterberg H, Buchhave P et al (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. *Lancet Neurol* 5:228–234. [https://doi.org/10.1016/S1474-4422\(06\)70355-6](https://doi.org/10.1016/S1474-4422(06)70355-6)
- Mattsson N, Zetterberg H, Hansson O et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA* 302:385–393. <https://doi.org/10.1001/jama.2009.1064>
- Prestia A, Caroli A, Wade SK et al (2015) Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. *Alzheimers Dement* 11:1191–1201. <https://doi.org/10.1016/j.jalz.2014.12.001>
- Prestia A, Caroli A, Herholz K et al (2013) Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. *Alzheimers Dement* 9:677–686. <https://doi.org/10.1016/j.jalz.2012.09.016>
- Shaffer JL, Petrella JR, Sheldon FC et al (2013) Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. *Radiology* 266:583–591. <https://doi.org/10.1148/radiol.12120010>
- Yu P, Dean RA, Hall SD et al (2012) Enriching amnesic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. *J Alzheimers Dis* 32:373–385. <https://doi.org/10.3233/JAD-2012-120832>
- Frisoni GB, Pievani M, Testa C et al (2007) The topography of grey matter involvement in early and late onset Alzheimer's disease. *Brain* 130:720–730. <https://doi.org/10.1093/brain/awl1377>
- Moller C, Vrenken H, Jiskoot L et al (2013) Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. *Neurobiol Aging* 34:2014–2022. <https://doi.org/10.1016/j.neurobiolaging.2013.02.013>
- Bouwman FH, Schoonenboom NSM, Verwey NA et al (2009) CSF biomarker levels in early and late onset Alzheimer's disease. *Neurobiol Aging* 30:1895–1901. <https://doi.org/10.1016/j.neurobiolaging.2008.02.007>
- Ossenkoppele R, Zwan MD, Tolboom N et al (2012) Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. *Brain* 135:2115–2125. <https://doi.org/10.1093/brain/aws113>
- Schmand B, Eikelenboom P, van Gool WA (2011) Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts. *J Am Geriatr Soc* 59:1705–1710. <https://doi.org/10.1111/j.1532-5415.2011.03539.x>
- Matsunari I, Samuraki M, Chen W-P et al (2007) Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. *J Nucl Med* 48:1961–1970. <https://doi.org/10.2967/jnumed.107.042820>
- Mattsson N, Rosen E, Hansson O et al (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. *Neurology* 78:468–476. <https://doi.org/10.1212/WNL.0b013e3182477eed>
- Chiaravalloti Agostino, Koch Giacomo, Toniolo Sofia, Belli Lorenza, Di Lorenzo Francesco, Gaudenzi Sara, Schillaci Orazio, Bozzali Marco, Giuseppe Sancesario AM (2016) Comparison between early-onset and late-onset Alzheimer's disease patients with amnesic presentation: CSF and 18-F-FDG PET study. *Dement Geriatr Cogn Dis Extra* 6:108–119. <https://doi.org/10.1159/000441776>
- Vanhoutte M, Semah F, Rollin Sillaire A et al (2017) 18F-FDG PET hypometabolism patterns reflect clinical heterogeneity in sporadic forms of early-onset Alzheimer's disease. *Neurobiol Aging*. <https://doi.org/10.1016/j.neurobiolaging.2017.08.009>
- Falgàs N, Tort-Merino A, Balasa M et al (2019) Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment. *Eur J Neurol*. <https://doi.org/10.1111/ene.13945>
- Verclytte S, Lopes R, Lenfant P et al (2016) Cerebral hypoperfusion and hypometabolism detected by arterial spin labeling MRI and FDG-PET in early-onset Alzheimer's disease. *J Neuroimaging*. <https://doi.org/10.1111/jon.12264>
- Li K, Chan W, Doody RS et al (2017) Prediction of conversion to Alzheimer's disease with longitudinal measures and time-to-event data. *J Alzheimers Dis*. <https://doi.org/10.3233/JAD-161201>
- Petersen RC, Smith GE, Waring SC et al (1999) Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* 56:303–308
- O'Bryant SE, Humphreys JD, Smith GE et al (2008) Detecting dementia with the mini-mental state examination in highly educated individuals. *Arch Neurol* 65:963–967. <https://doi.org/10.1001/archneur.65.7.963>
- Hensel A, Angermeyer MC, Riedel-Heller SG (2007) Measuring cognitive change in older adults: reliable change indices for the mini-mental state examination. *J Neurol Neurosurg Psychiatry* 78:1298–1303. <https://doi.org/10.1136/jnnp.2006.109074>
- McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 34:939–944

28. Herholz K, Salmon E, Perani D et al (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. *Neuroimage* 17:302–316
29. Orimo H, Ito H, Suzuki T et al (2006) Reviewing the definition of “elderly”. *Geriatr Gerontol Int* 6:149–158. <https://doi.org/10.1111/j.1447-0594.2006.00341.x>
30. Blagosklonny MV (2010) Why human lifespan is rapidly increasing: solving “longevity riddle” with “revealed-slow-aging” hypothesis. *Aging (Albany NY)*. <https://doi.org/10.18632/aging.100139>
31. Jacobs JM, Maaravi Y, Cohen A et al (2012) Changing profile of health and function from age 70 to 85 years. *Gerontology*. <https://doi.org/10.1159/000335238>
32. Mendez MF (2017) Early-onset Alzheimer disease. *Neurol Clin* 35:263–281. <https://doi.org/10.1016/j.ncl.2017.01.005>
33. Prestia A, Caroli A, van der Flier WM et al (2013) Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. *Neurology* 80:1048–1056. <https://doi.org/10.1212/WNL.0b013e3182872830>
34. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 44:837–845
35. Therneau T, Grambsch PM (2000) *Modeling survival data: extending the Cox model*. Springer, New York
36. Schmand B, Eikelenboom P, van Gool WA (2012) Value of diagnostic tests to predict conversion to Alzheimer’s disease in young and old patients with amnesic mild cognitive impairment. *J Alzheimers Dis* 29:641–648. <https://doi.org/10.3233/JAD-2012-111703>
37. van Rossum IA, Vos SJB, Burns L et al (2012) Injury markers predict time to dementia in subjects with MCI and amyloid pathology. *Neurology* 79:1809–1816. <https://doi.org/10.1212/WNL.0b013e3182704056>
38. Landau SM, Lu M, Joshi AD et al (2013) Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β -amyloid. *Ann Neurol* 74:826–836. <https://doi.org/10.1002/ana.23908>
39. Zwan M, van Harten A, Ossenkoppele R et al (2014) Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. *J Alzheimers Dis* 41:801–807. <https://doi.org/10.3233/JAD-132561>
40. Caroli A, Prestia A, Chen K et al (2012) Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. *J Nucl Med* 53:592–600. <https://doi.org/10.2967/jnumed.111.094946>
41. Haense C, Herholz K, Jagust WJ, Heiss WD (2009) Performance of FDG PET for detection of Alzheimer’s disease in two independent multicentre samples (NEST-DD and ADNI). *Dement Geriatr Cogn Disord* 28:259–266. <https://doi.org/10.1159/000241879>
42. Herholz K, Westwood S, Haense C, Dunn G (2011) Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. *J Nucl Med* 52:1218–1226. <https://doi.org/10.2967/jnumed.111.090902>
43. Frisoni GB, Fox NC, Jack CRJ et al (2010) The clinical use of structural MRI in Alzheimer disease. *Nat Rev Neurol* 6:67–77. <https://doi.org/10.1038/nrneuro.2009.215>
44. Bobinski M, Wegiel J, Wisniewski HM et al (1996) Neurofibrillary pathology—correlation with hippocampal formation atrophy in Alzheimer disease. *Neurobiol Aging* 17:909–919
45. Apostolova LG, Zarow C, Biado K et al (2015) Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI harmonized hippocampal segmentation protocol. *Alzheimers Dement* 11:139–150. <https://doi.org/10.1016/j.jalz.2015.01.001>
46. den Heijer T, van der Lijn F, Koudstaal PJ et al (2010) A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. *Brain* 133:1163–1172. <https://doi.org/10.1093/brain/awq048>
47. Palasí A, Gutiérrez-Iglesias B, Alegret M et al (2015) Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? *J Neurol* 262:1238–1246. <https://doi.org/10.1007/s00415-015-7698-3>

Affiliations

Daniele Altomare^{1,20}  · Clarissa Ferrari²  · Anna Caroli³  · Samantha Galluzzi⁴ · Annapaola Prestia⁴ · Wiesje M. van der Flier^{5,6} · Rik Ossenkoppele^{5,7,8} · Bart Van Berckel^{5,7} · Frederik Barkhof^{7,9,10}  · Charlotte E. Teunissen¹¹ · Anders Wall¹² · Stephen F. Carter^{13,14} · Michael Schöll^{8,21,22} · IL Han Choo^{13,15} · Timo Grimmer¹⁶ · Alberto Redolfi⁴ · Agneta Nordberg^{17,18} · Philip Scheltens⁵ · Alexander Drzezga¹⁹ · Giovanni B. Frisoni^{1,4,20}  · for the Alzheimer’s Disease Neuroimaging Initiative

¹ Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland

² Service of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, via Pilastroni 4, 25125 Brescia, Italy

³ Medical Imaging Unit, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy

⁴ Laboratory of Alzheimer’s Neuroimaging and Epidemiology (LANE), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

⁵ Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

⁶ Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

⁷ Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

⁸ Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden

⁹ Institute of Neurology, UCL, London, UK

¹⁰ Institute of Healthcare Engineering, UCL, London, UK

¹¹ Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

- ¹² Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
- ¹³ Alzheimer Neurobiology Center, Karolinska Institutet, Stockholm, Sweden
- ¹⁴ Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
- ¹⁵ Department of Neuropsychiatry, School of Medicine, Chosun University, Gwangju, Republic of Korea
- ¹⁶ Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
- ¹⁷ Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
- ¹⁸ Aging Theme, Karolinska University Hospital, Stockholm, Sweden
- ¹⁹ Department of Nuclear Medicine, University of Cologne, Cologne, Germany
- ²⁰ Memory Clinic, University Hospital of Geneva, Geneva, Switzerland
- ²¹ Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
- ²² Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK